American Heart Association's New Scientific Statement Deems

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
61
American Heart Association's New Scientific Statement Deems the Corus CAD Test Valid and Useful for Clinicians Evaluating Obstructive CAD

REDWOOD CITY, CA--(Marketwired - Sep 28, 2017) - CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, announced today that in a Scientific Statement by the American Heart Association, the Corus® CAD blood test was evaluated and "deemed to be valid and useful" in the workup of patients with suspected coronary artery disease (CAD). 1 CAD is one of the leading causes of death in the U.S. resulting in one in seven deaths. 2

Published in the peer-reviewed journal, Circulation: Cardiovascular Genetics, the AHA Scientific Statement, The Expressed Genome in Cardiovascular Disease and Stroke: Refinement, Diagnosis, and Prediction: A Scientific Statement From the American Heart Association , 1 discussed how the expressed genome can now, and in the future, be used to diagnose and predict cardiovascular disease and manage patient treatment. The statement then highlighted two commercially available technologies stemming from this research.

"Since the human genome was sequenced 14 years ago, significant advancements have been made in the field of expressed genome research," said Kiran Musunuru, M.D., Ph.D., the statement's lead author and Associate Professor of Cardiovascular Medicine and Genetics at the University of Pennsylvania. "The AHA convened a panel of experts to review, evaluate and publish the state of the science in the diagnosis and prediction of cardiovascular disease with these technologies. We are optimistic that their use and application will continue to grow, enabling their widespread adoption and progress in this field. Our work identified two available tests that had generated sufficient data to be included in our review, including Corus CAD."

Corus CAD is the only clinically validated blood test that uses age, sex and gene expression to measure the current likelihood of obstructive coronary artery disease* (CAD) in symptomatic patients. The test was validated in both the PREDICT 3 and COMPASS 4 clinical studies. And the results were then independently confirmed in a third study -- the NHLBI-sponsored PROMISE Corus CAD substudy . 5 With a 96% negative predictive value, the Corus CAD test is a simple blood test that incorporates age, sex, and gene expression measurements into a single score (1-40 scale) corresponding to the current likelihood of obstructive CAD. 4,6

"We are delighted that the American Heart Association highlighted the clinical value of the Corus CAD test in the recent Scientific Statement," says Khush F. Mehta, President and Chief Executive Officer of CardioDx. "With Corus CAD , CardioDx is delivering on the promise of the human genome by empowering clinicians with enhanced solutions for better patient care."

About Obstructive Coronary Artery Disease Coronary artery disease (CAD) is a very common heart condition in the United States. One in seven deaths among Americans is caused by CAD. 2 CAD can cause a narrowing or blockage of the coronary arteries (vessels to the heart that supply the heart with blood, oxygen, and nutrients), reducing blood flow to the heart muscle. This narrowing or blockage in the coronary arteries is often referred to as obstructive CAD, characterized by the presence of atherosclerosis, or plaque.

About the Corus CAD Test Corus CAD is the first and only commercially available blood test that can safely and conveniently help primary care clinicians and cardiologists assess whether or not a stable non-diabetic patient's symptoms may be due to obstructive coronary artery disease. The test incorporates age, sex and gene expression measurements into a single score that indicates the likelihood of obstructive CAD. Clinicians use the Corus CAD score, along with other clinical information, to determine whether further cardiac testing is necessary, which can help patients avoid unnecessary exposure to radiation associated with medical imaging testing, as well as possible reactions to imaging dyes and/or potential complications from invasive cardiac procedures. The test involves a routine blood draw that is conveniently administered in the clinician's office. The Corus CAD test is the only sex-specific test for the evaluation of obstructive CAD because it accounts for cardiovascular differences between men and women.

The test has been clinically validated in independent male and female patient cohorts, including two prospective, multicenter U.S. studies, PREDICT and COMPASS. 3,4 In the COMPASS study, the Corus CAD test outperformed myocardial perfusion imaging (MPI) as a diagnostic tool to exclude obstructive CAD by demonstrating a higher negative predictive value (96% vs. 88%, p < 0.001) than MPI for assessing the presence of obstructive CAD. 6 In the NHLBI-sponsored PROMISE Corus CAD substudy, Corus CAD demonstrated similar clinical outcomes to MPI and coronary CT-angiography at 25 months follow-up (3.2% vs. 2.6%, p=0.29). 5 To date, over 240,000 Corus CAD test results have been provided to clinicians commercially. CardioDx processes all Corus CAD test samples at its CLIA-certified and CAP-accredited clinical laboratory in Redwood City, California.

The Corus CAD test has been recognized by The Wall Street Journal's Technology Innovation Awards, honored as a Gold Edison Award recipient, and named one of TIME's Top 10 Medical Breakthroughs.

About CardioDx CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, is committed to developing clinically validated tests that empower clinicians to better tailor care to each individual patient. Strategically focused on coronary artery disease, CardioDx is committed to expanding patient access and improving healthcare quality and efficiency through the commercialization of genomic technologies. Please visit www.cardiodx.com for additional information.

* Obstructive CAD is defined as at least one atherosclerotic plaque causing ≥50% luminal diameter stenosis in a major coronary artery (≥1.5 mm lumen diameter) as determined by invasive quantitative coronary angiography (QCA) or coronary computed tomography angiography (CTA) (≥2.0 mm).

References

1 Musunuru K, Ingelsson E, Fornage M, et al. The Expressed Genome in Cardiovascular Diseases and Stroke: Refinement, Diagnosis, and Prediction: A Scientific Statement From the American Heart Association. Circ Cardiovasc Genet. 2017;10(4):e1-e25. 2 Benjamin EJ, Blaha MJ, Chiuve SE, et al. On Behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics - 2017 Update: A Report from the American Heart Association. Circulation . 2017;135(10):e146-e603. 3 Rosenberg S, Elashoff MR, Beineke P, et al. Multicenter Validation of the Diagnostic Accuracy of a Blood-Based Gene Expression Test for Assessing Obstructive Coronary Artery Disease in Nondiabetic Patients. Ann Intern Med . 2010;153:425-434. 4 Thomas GS, Voros S, McPherson JA, et al. A Blood-Based Gene Expression Test for Obstructive Coronary Artery Disease Tested in Symptomatic Nondiabetic Patients Referred for Myocardial Perfusion Imaging: The COMPASS Study. Circ Cardiovasc Genet . 2013;6(2):154-162. 5 Voora D, Coles A, Lee KL, et al. An Age- and Sex-Specific Gene Expression Score is Associated With Revascularization and Coronary Artery Disease: Insights From the Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) Trial.  Am Heart J . 2017;184:133-140. 6 The COMPASS study demonstrated that the Corus CAD algorithm has an NPV of 96% at the pre-specified threshold of 15 in a population of men and women referred to MPI.

For media inquiries, please contact: Glenn Silver Lazar Partners +1-212-871-8485 gsilver@lazarpartners.com .

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 175

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 308

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 350

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 272

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 23

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 225

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 246

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 232

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 377

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 156

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading

Top 5 Most Recently Viewed Articles

Zixi Unveils Advanced Video Solutions for Live Sports in 2025

Updated Category News Views 319

Zixi's Innovative Showcase at IBC 2025 IBC stand 5.A85 Zixi, the Emmy Award-winning leader in broadcast-quality live video over IP, is set to exhibit at IBC 2025 held in Amsterdam. At Stand 5.A85, the company will reveal groundbreaking innovations aimed at enhancing the live video experience for broadcasters, sports leagues, service providers, and OTT platforms. With a...

Continue Reading
Discover the Incredible Growth of Agnico Eagle Mines Over 20 Years

Updated Category News Views 165

Discovering the Long-Term Success of Agnico Eagle Mines Agnico Eagle Mines (NYSE: AEM) has demonstrated impressive performance in the stock market over the last 20 years. With a remarkable average annual return of 9.52%, the company has outperformed the market by 1.17% each year. Currently, Agnico Eagle holds a market valuation of $41.72 billion, showcasing its strong...

Continue Reading
Join the Race for Excellence in Bartending Skills Today

Updated Category News Views 276

USBG Presents World Class Sponsored By DIAGEO Launches Bartender Competition The esteemed bartending competition is now open for applications, inviting skilled mixologists to step into the limelight for a chance to become the 2025 U.S. Bartender of the Year. With application deadlines coming up quickly, anyone with the passion, creativity, and skill should take advantage...

Continue Reading
Sunflower Therapeutics Secures $3 Million SAFE for Future Growth

Updated Category News Views 370

Sunflower Therapeutics Secures Oversubscription of $3 Million SAFE Sunflower Therapeutics, a public benefit corporation dedicated to improving global protein manufacturing, recently announced the successful oversubscription of a $3 million Simple Agreement for Future Equity (SAFE). This achievement illustrates strong investor confidence in the company's mission to enhance...

Continue Reading
Future Growth of Video Surveillance Market Projected to Soar

Updated Category News Views 42

Forecast for Video Surveillance Market Growth The video surveillance market is witnessing remarkable expansion, with a projected value of USD 54.42 billion by the year 2024 and an impressive rise to USD 88.71 billion anticipated by 2030. This growth represents a compounded annual growth rate (CAGR) of 8.5% during the upcoming forecast period. Various factors contribute to...

Continue Reading